PYC Therapeutics shares (ASX: PYC) just delivered the worst decline in recent memory today, falling back 10.46% to claim the unwanted title of worst performer on the ASX 200. Despite today’s damage, PYC remains up 31.48% YTD, and has more than doubled from its 52-week low of A$1.04, with a TTM gain of 96.33. The question now is whether Tuesday’s breakdown represents distribution, or simply a healthy shakeout within a broader uptrend.
From a technical perspective, today’s sell-off points to a short term shift in momentum. PYC shares broke below both the 30 day and 50 day SMAs in the session, alongside the A$2.20 price level that had served as both resistance during the mid-year rally and support during the recent pullback.
What is driving PYC Therapeutics shares?
PYC Therapeutics is a Perth-based clinical-stage biotechnology company developing peptide-conjugated RNA therapeutics for rare monogenic diseases. Its lead programs span two therapeutic areas: rare kidney disease and ophthalmology.
In the kidney program, PYC-003 targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a condition affecting millions globally with limited disease-modifying options currently available. The company recently dosed the first patient in an Open-Label Extension (OLE) study, advancing to a Phase 1b higher dose cohort of 2.4 mg/kg with continuous dosing planned for up to 24 months. Data presentations are anticipated at major nephrology conferences including the American Society of Nephrology (ASN) annual meeting, making the coming months a potentially significant period for the stock’s fundamental narrative.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
On the ophthalmology side, VP-001 and PYC-001 are advancing in Retinitis Pigmentosa (RP11) and Autosomal Dominant Optic Atrophy (ADOA) respectively — both rare, genetically defined conditions where no approved therapies currently exist.
The recent high came after the S&P Dow Jones Indices confirmed PYC’s inclusion in the S&P/ASX 300 during the quarterly rebalance. Once passive ETF buying associated with the rebalancing was absorbed, the marginal buyer disappeared and profit-taking from shorter-term momentum participants began in earnest, a textbook sell-the-news dynamic that has played out across small-cap index inclusions before.
Operationally, PYC’s Q3 2026 investor update outlined an accelerating transition from early-stage research toward late-stage clinical development. The company expanded its executive bench, adding a Chief Clinical Development Officer and dedicated program leads, signalling an intent to run multiple late-stage programs simultaneously. Management also flagged ongoing evaluation of a potential U.S. dual-listing, a move that would theoretically open access to the deeper pool of specialist biotech capital available on NASDAQ.
A strong move YTD, with shifting momentum leaving more questions than answers about what comes next. The 26% pullback in three weeks leaves the stock in a technical bear market near term, even if the longer term trend remains in tact.
Bull Case:
- Phase 1b kidney data readout could swiftly reignite institutional buying interest
- ASX 300 inclusion provides lasting structural liquidity and expanded institutional coverage
- Stock remains up over 100% year-on-year despite the recent sharp correction
- RNA platform addresses multiple rare diseases with significant unmet medical need
Bear Case:
- Breach of A$2.20 support signals technical momentum has shifted decisively lower
- Rising Australian bond yields compress valuations on pre-revenue long-dated growth assets
- Late-stage clinical expansion will materially increase cash burn and dilution risk
- Binary clinical readout risk could severely de-rate shares on any disappointing data
